Latigo Biotherapeutics Reports Q3 Financials and Pipeline Progress
The company reported $401 million in cash and expects to initiate Phase 3 trials for onzotrigine, with topline results anticipated in 2027, demonstrating strong financial footing to advance non-opioid pain candidates.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed